Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569016890> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2569016890 endingPage "2018" @default.
- W2569016890 startingPage "2018" @default.
- W2569016890 abstract "2018 Background: Current standard treatment for GBM consists in radiotherapy (RT) plus concomitant and adjuvant (adj) TMZ. Myelosupression is the dose limiting toxicity of TMZ with grade 3 and 4 cytopenia occurring in ~16%. We describe the difference in outcome of newly diagnosed GBM patients treated with TMZ who developed grade 3 and 4 cytopenia. Methods: A 10-year retrospective analysis of newly diagnosed adult GBM patients (pts) treated with first-line TMZ. All pts received concurrent TMZ and RT with or without investigational drug. If the pt did not progress on magnetic resonance imaging (MRI) adj TMZ was given. Cytopenia events during TMZ therapy were graded using the National Cancer Institute Common Toxicity Criteria (v3). Survival distribution was estimated by the Kaplan-Meier method. Results: Of 191 pts, 23% developed grade 3 and 4 cytopenia. 74% pts were ≤ 65 years, 75% had 80-100% karnofsky performance status and 78% had surgical resection at diagnosis. 93% pts received 6 wks of concurrent RT 60 Gy and TMZ 75 mg/m2/d. The median dose of adj TMZ was 150-200 mg/m2/d1-d5 every 28d cycle. The median cycles was 4 (range, 0-24). The median progression free survival (PFS) was 6.7 months (mo). The 6 mo and 12 mo PFS for pts who had grade 3 and 4 cytopenia was 73% (95% confidence interval [CI], 57%-83%) and 33% (95% CI, 20%-47%); while in pts with no grade 3 and 4 cytopenia was 51% (95% CI, 43%-59%) and 24% (95% CI, 17.9%-31.8%). The unadjusted hazard ratio (HR) for death or disease progression of pts with grade 3 and 4 cytopenia, as compared to those without grade 3 and 4 cytopenia, was 0.58 [95% CI, 0.40 to 0.82; p< 0.003]. The HR for death or disease progression was 0.68 (95% CI, 0.47-0.98; p<0.045) among those with a methylated MGMT promoter. The total dose of TMZ was not different between both groups (p=0.284 by Wilcoxon rank sum test). Conclusions: Our study supports that newly diagnosed GBM pts who develop grade 3 and 4 cytopenia during TMZ therapy have improved PFS. Further clinical trials are required to validate grade 3 and 4 cytopenia as a potential biomarker for TMZ efficacy in an attempt to optimize and personalize GBM therapy." @default.
- W2569016890 created "2017-01-13" @default.
- W2569016890 creator A5010706893 @default.
- W2569016890 creator A5040892823 @default.
- W2569016890 creator A5068195644 @default.
- W2569016890 creator A5070193149 @default.
- W2569016890 creator A5070737018 @default.
- W2569016890 date "2011-05-20" @default.
- W2569016890 modified "2023-09-27" @default.
- W2569016890 title "Outcome of grade 3 and 4 cytopenia in newly diagnosed glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ)." @default.
- W2569016890 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.2018" @default.
- W2569016890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28023868" @default.
- W2569016890 hasPublicationYear "2011" @default.
- W2569016890 type Work @default.
- W2569016890 sameAs 2569016890 @default.
- W2569016890 citedByCount "0" @default.
- W2569016890 crossrefType "journal-article" @default.
- W2569016890 hasAuthorship W2569016890A5010706893 @default.
- W2569016890 hasAuthorship W2569016890A5040892823 @default.
- W2569016890 hasAuthorship W2569016890A5068195644 @default.
- W2569016890 hasAuthorship W2569016890A5070193149 @default.
- W2569016890 hasAuthorship W2569016890A5070737018 @default.
- W2569016890 hasConcept C126322002 @default.
- W2569016890 hasConcept C141071460 @default.
- W2569016890 hasConcept C143998085 @default.
- W2569016890 hasConcept C2777389519 @default.
- W2569016890 hasConcept C2780007613 @default.
- W2569016890 hasConcept C2780366003 @default.
- W2569016890 hasConcept C509974204 @default.
- W2569016890 hasConcept C71924100 @default.
- W2569016890 hasConceptScore W2569016890C126322002 @default.
- W2569016890 hasConceptScore W2569016890C141071460 @default.
- W2569016890 hasConceptScore W2569016890C143998085 @default.
- W2569016890 hasConceptScore W2569016890C2777389519 @default.
- W2569016890 hasConceptScore W2569016890C2780007613 @default.
- W2569016890 hasConceptScore W2569016890C2780366003 @default.
- W2569016890 hasConceptScore W2569016890C509974204 @default.
- W2569016890 hasConceptScore W2569016890C71924100 @default.
- W2569016890 hasIssue "15_suppl" @default.
- W2569016890 hasLocation W25690168901 @default.
- W2569016890 hasOpenAccess W2569016890 @default.
- W2569016890 hasPrimaryLocation W25690168901 @default.
- W2569016890 hasRelatedWork W2002120878 @default.
- W2569016890 hasRelatedWork W2003938723 @default.
- W2569016890 hasRelatedWork W2029933304 @default.
- W2569016890 hasRelatedWork W2034544297 @default.
- W2569016890 hasRelatedWork W2047967234 @default.
- W2569016890 hasRelatedWork W2118496982 @default.
- W2569016890 hasRelatedWork W2128503410 @default.
- W2569016890 hasRelatedWork W2439875401 @default.
- W2569016890 hasRelatedWork W3194058763 @default.
- W2569016890 hasRelatedWork W2525756941 @default.
- W2569016890 hasVolume "29" @default.
- W2569016890 isParatext "false" @default.
- W2569016890 isRetracted "false" @default.
- W2569016890 magId "2569016890" @default.
- W2569016890 workType "article" @default.